miR-200c inhibits metastasis of breast cancer cells by targeting HMGB1

Abstract

miR-200c has been shown to regulate the epithelial-mesenchymal transition (EMT) by inhibiting ZEB1 and ZEB2 expression in breast cancer cells. This study further examined the role of miR-200c in the invasion and metastasis of breast cancer that goes beyond the regulation on ZEB1 and ZEB2 expression. In this study, the bioinformatics software (miRanda) was used to predict the target gene of miR-200c and Renilla luciferase assay to verify the result. The metastatic breast cancer cells MDA-MB-231 were cultured and transfected with the miR-200c mimic or inhibitor. The expressions of miR-200c and HMGB1 were detected by RT-PCR and Western blotting, respectively. Transwell assay and wound healing assay were employed to examine the invasive and migrating ability of transfected cells. Target prediction and Renilla luciferase analysis revealed that HMGB1 was a putative target gene of miR-200c. After transfection of MDA-MB-231 cells with the miR-200c mimic or inhibitor, the expression of miR-200c was significantly increased or decreased when compared with cells transfected with the miR-200c mimic NC or inhibitor NC. Moreover, the expression of HMGB1 was reversely correlated with that of miR-200c in transfected cells. Tranwell assay showed that the number of invasive cells was significantly reduced in miR-200c mimic group when compared with miR-200c inhibitor group. It was also found that the migrating ability of cells transfected with miR-200c mimics was much lower than that of cells transfected with miR-200c inhibitors. It was suggested that miR-200c can suppress the invasion and migration of breast cancer cells by regulating the expression of HMGB1. miR-200c and HMGB1 may become useful biomarkers for progression of breast cancer and targets of gene therapy.

Keywords

breast cancer / miR-200c / HMGB1 / metastasis

References

[1] SiegelR, NaishadhamD, JemalA. Cancer statistics, 2013. CA Cancer J Clin, 2013, 63(1): 11-30

[2] JiangP, EnomotoA, TakahashiM. Cell biology of the movement of breast cancer cells: intracellular signaling and the actin cytoskeleton. Cancer Lett, 2009, 284(2): 122-130

[3] GravesP, ZengY. Biogenesis of mammalian microRNAs: a global view. Genomics Proteomics Bioinformatics, 2012, 10(5): 239-245

[4] MacfarlaneLA, MurphyPR. MicroRNA: biogenesis, function and role in cancer. Curr Genomics, 2010, 11(7): 537-561

[5] BurkU, SchubertJ, WellnerU, et al.. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep, 2008, 9(6): 582-589

[6] PeterME. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle, 2009, 8(6): 843-852

[7] ShimonoY, ZabalaM, ChoRW, et al.. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell, 2009, 138(3): 592-603

[8] SchickelR, ParkSM, MurmannAE, et al.. mir-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell, 2010, 38(6): 908-915

[9] ChangCJ, ChaoCH, XiaW, et al.. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol, 2011, 13(3): 317-323

[10] CochraneDR, SpoelstraNS, HoweEN, et al.. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther, 2009, 8(5): 1055-1066

[11] LinJ, LiuC, GaoF, et al.. miR-200c enhances radiosensitivity of human breast cancer cells. J Cell Biochem, 2013, 114(3): 606-615

[12] AhmadA, AboukameelA, KongD, et al.. Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res, 2011, 71(9): 3400-3409

[13] HoweEN, CochraneDR, CittellyDM, et al.. miR-200c targets a NF-κB up-regulated TrkB/NTF3 autocrine signaling loop to enhance anoikis sensitivity in triple negative breast cancer. PLoS One, 2012, 7(11): e49987

[14] JurmeisterS, BaumannM, BalwierzA, et al.. MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Mol Cell Biol, 2012, 32(3): 633-651

[15] ChenY, SunY, ChenL, et al.. miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. Mol Med Rep, 2013, 7(5): 1579-1584

[16] NikoletopoulouV, MarkakiM, PalikarasK, et al.. Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta, 2013, 1833(12): 3448-3459

[17] KoYB, KimBR, NamSL, et al.. High-mobility group box 1 (HMGB1) protein regulates tumor-associated cell migration through the interaction with BTB domain. Cell Signal, 2014, 26(4): 777-783

[18] TangD, KangR, ZehHJ3rd, et al.. High-mobility group box 1 and cancer. BBA, 2010, 1799(1–2): 131-140

[19] SparatoreB, PatroneM, PassalacquaM, et al.. Activation of A431 human carcinoma cell motility by extracellular high-mobility group box 1 protein and epidermal growth factor stimuli. Biochem J, 2005, 389(1): 215-221

[20] BrezniceanuML, VölpK, BösserS, et al.. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J, 2003, 17(10): 1295-1297

[21] LiveseyKM, KangR, VernonP, et al.. p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res, 2012, 72(8): 1996-2005

[22] van BeijnumJR, Nowak-SliwinskaP, van den BoezemE, et al.. Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene, 2013, 32(3): 363-374

[23] JiaoY, WangHC, FanSJ. Growth suppression and radiosensitivity increase by HMGBI in breast cancer. Acta pharmacologica Sinica, 2007, 28(12): 1957-1967

[24] BernardiniM, LeeCH, BeheshtiB e a1. High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia, 2005, 7(6): 603-613

[25] BarnesKR, KutikovA, LippardSJ. Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum (IV) complexes. Chem Biol, 2004, 11(4): 557-564

[26] GregoryPA, BrackenCP, SmithE, et al.. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell, 2011, 22(10): 1686-1698

[27] TobarN, VillarV, SantibanezJF. ROS-NFkappaB mediates TGF-beta1-induced expression of urokinase-type plasminogen activator, matrix metalloproteinase-9 and cell invasion. Mol Cell Biochem, 2010, 340(1–2): 195-202

[28] ChuaHL, Bhat-NakshatriP, ClareSE. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene, 2007, 26(5): 711-724

[29] WuX, MiY, YangH, et al.. The activation of HMGB 1 as a progression factor on inflammation response in normal human bronchial epithelial cells through RAGE/JNK/NF-κB pathway. Mol Cell Biochem, 2013, 380(1–2): 249-257

[30] SmolarczykR, CichońT, JaroszM, et al.. HMGB1—its role in tumor progression and anticancer therapy. Postepy Hig Med Dosw, 2012, 22(66): 913-920